Modality
ERT
MOA
PRMT5i
Target
IL-17A
Pathway
Checkpoint
MCLCTCLAS
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
Jun 2022
→ Jul 2025
Phase 1Current
NCT07440100
975 pts·CTCL
2022-06→2025-07·Active
975 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-109mo agoPh2 Data· CTCL
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1/2
Active
Catalysts
Ph2 Data
2025-07-10 · 9mo ago
CTCL
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07440100 | Phase 1/2 | CTCL | Active | 975 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP |